GSK registers large new Shingrix cardiovascular trial; DESTINY HES study update posted

GSK had two clinical trial registry updates for the week of October 13, 2026.

• GSK registered a new Phase 3a trial, NCT07872046, evaluating the effect of the recombinant zoster vaccine on major adverse cardiovascular events in adults with established cardiovascular disease or with 2 or more cardiovascular risk factors.¹ The study is listed as not yet recruiting, with an estimated start of November 30, 2026 and planned enrollment of 16,390 participants.¹ The primary outcome is time to first occurrence of composite 3-point MACE, defined as non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, measured up to Month 74.¹
• GSK's Phase 3 "DESTINY" trial of depemokimab (NCT05334368) in hypereosinophilic syndrome (HES) had its record updated. The study remains active, not recruiting, with actual enrollment of 110 participants². The primary outcome is frequency of HES flares over up to 52 weeks², and primary completion is estimated for October 29, 2027.